Abstract
The Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study was designed to evaluate the hypothesis that carvedilol, a beta-blocker with important differences from other beta-blockers, would be effective in reducing mortality and morbidity in post-myocardial-infarction patients with poor left ventricular function. Because of slow recruitment and a lower than expected event rate, the monitoring committee was asked to advise on a change in the primary endpoint of total mortality. This it did, but the new co-primary endpoints were negative, whereas if the original primary endpoint had been retained, the result would have been strongly positive.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Norwegian Multicentre Group. 1981. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807.
ß-Blocker Heart Attack Trial Research Group. 1982. A randomised trial of propranolol in patients with acute myocardial infarction JAMA 247:1707–1714.
Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. 1975. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022–1023.
Dargie HJ on behalf of the CAPRICORN Investigators. 2000. Design and methodology of the CAPRICORN trial-a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2:325–332.
CIBIS-II Investigators. 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353:9–13.
MERIT-HF Study Group. 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353:2001–2007.
CAPRICORN Investigators. 2001. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:The CAPRICORN randomised trial. Lancet 357:1385–1390.
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. 2002. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194–2199.
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Cardiovascular and Renal Drugs Advisory Committee, 98th Meeting, January 7, 2003. www.fda.gov/ohrms/dockets/ac/03/transcripts/3920T2.htm
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Julian, D.G. (2006). The Data Monitoring Experience in the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study: Hazards of Changing Primary Outcomes. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_33
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_33
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)